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Mycloma cells absolutely rcquirc inlerlcukin-6 (IL-6) for growing in vivo in patients with multiple mycloma nd cxogcnous IL-bdcpcndcnt myclomn 
cell lines have been reproducibly obtained. In this study WC show a dramatic up-rcgulution of the IL-6 receptor (gp80 chain) gcnc expression in 
mycloma ccl1 lines following ihu removal of exogenous IL-6. Such a rcguluion was also known to occur in IL-6-deprived mycloma cells in vivo 
in three patients who were treated with optimal doses of anti-IL-6 monoclonul antibodies. The direct erect of IL-6 on IL-G receptor gene expression 
in myclonra cells was further confirmed by adding IL-6 to an autonomously growing mycloma cell line. 
I L-6; I L-6 rcccpior: M ultiplc mycloma 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Intcrleukin-6 (IL-B) is a pleitotropic cytokine which 
is produced by various types of cells [1,2]. Among its 
numerous biological properties, IL-6 induces the tcrmi- 
nal differentiation of 6 cells [3], the proliferation of 
murine hybridoma and plasmacytoma cells [4], and is 
a potent growth factor for human myeloma cells in vitro 
[5-81. IL-6 is produced in large amounts in vivo in pa- 
tients with active multiple myeloma (MM) [5,9,10], and 
we have recently shown that the injection of anti-IL-6 
monoclonal antibodies (MAbs) could block IL-6 bioac- 
tivity and myeloma-cell proliferation in vivo in patients 
with terminal disease [I I]. The IL-6 receptor (IL-6R) 
was shown to be expressed on a number of cells includ- 
ing myeloma cells [I Z-141, and the regulation of its 
expression by cytokines or other agents has already 
been studied in different ypes of cells [IS-I 71. By taking 
advantage of our recently obtained IL-6-dependent 
human myeloma cell lines (HMCL) and of the treat- 
ment of MM patients with anti-IL-6 MAbs, we report 
here that privation of IL-6 inducts an up-regulation of 
IL-6R gene expression in myeloma cells in vitro and 
also in vivo. 
Abbrcvi~triorrs: IL-6. inlcrlcukin-6: IL-6R, intcrleukind receptor; 
MM, multiple mycloma; HMCL, human mycloma cell line; MAb. 
monoclonal antibody. 
Corrcqmrzd~nw orfdrcs.~: B.Klein. INSERM lJ29 I, 99 rue Pucrh Villa, 
34090 Monlpellicr Ccdex, France. Fax: (33) (67) 04-1863. 
Patients A and B had plasma cell lcukcmia with respectively 52% 
IgG/Z and 65% lgA~ mycloma cells it1 the peripheral blood and patient 
C had Bcncc Jones mycloma whh pleural effusion containing 82% 
mycloma cells. Patients A, Band C were treated with anti-IL-6 MAbs 
as dcscribcd for one patient [I I]. Peripheral blood or pleural effusion 
samples were taken before the first anti-IL-6 MAb injection and on 
each day during the first 4 days of treatment. Mononuclear cells wcrc 
prepared by ccntrifugation of huparinizcd samples over Ficoll-Hypa 
quc gradients. For enrichment in myelomucclls and mononuclear cells 
wcrc dcplctcd for monocytcs, mycloid cells and T cells by incubation 
with a mixture of immunobcuds (Dynabcads M-450. Biosys. France) 
coutcd with specific MAbs (anti-CDI3, CDIS. CD3) as already dc- 
scribed [IO]. The autonomously growing RPM1 8226 [IS] HMCL was 
cultured in RPM1 1640 (Gibco BRL, France) conlaining 10% FCS. 
For XG-I, and XG-5 IL-6-dcpcndcnt HMCL. 2 nM human rccombi- 
nunt (hr) I L-6 was added in the medium cullure [ 191. 
The anti-CDIJ, anti-CDIS. and anti-CD3 MAbs WCE purchased 
from Immunotech (Marseilles, France); the hrlL-6 was kindly pro- 
vided by N. Vita and P. Fcrrara (Sanofi, Ldbkge. France). The anli 
IL-6 MAbs (B-E4 and B-E& 20) by J. Wijdencs (CRTS, Bcsanwn. 
Fruncc); the probe for human IL-GR (pBSF2R236, 14) by T. Hirdno 
(University of Osaka, Japan), for rat glyccraldchydc-3-phosphate dc- 
hydrogendsc(GAPDH)by M. Picchacryk(CNRSMontpcllicr, Franc@. 
2.3. ,k’cwrlrw~ hlof u,m/wl uttd ttzRiUA quorrfl/iuJrion 
Extraction of tolal RNA, elcctrophorctic conditions. blotting and 
mcnxrane hybridizations with both ILdR nnd GAPDH probes were 
done as already described [IO]. Autoradiograms were scanned on a 
Dual-wavclcngth TLC scanner CS-390 (Shimatzu. Japan). The 
amount of IL-6R mRNA in each lane wascvaluatcd in arbitrary unils 
after standardization with the amount of GAPDH mRNA. 
3. RESULTS 
We analyzed the effect of IL-6 on the gp80 IL-6R 
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Fig, I, Regulation of IL-6R gcnc expression in I-IMCL, XG-I. XG-5 
and RPM1 8226 were cultured with or without 9 nM hrlL-6 for 
various lengths of time. Cells w’crc harvested. total RNA wcrc cx- 
tracted and submitted to hybridizxion with both IL&R and GAPDH 
specific probes, Autoradiograms were scanned and IL-6R mRNA 
levels were quantified. Results for each HMCL itre expressed in per- 
centage of the control group as detailed in the text, 
gene expression in 3 HMCL by Northern blot hybridi- The regulation of IL-6R expression in myeloma cells 
zation. The amounts of IL-6R mRNA at each time in vivo was studied during treatment of terminal my- 
incubation and for each HMCL are expressed in pcr- eloma patients with anti-IL-6 MAbs. IN 3 patients with 
centage of the control group, i.e. cells incubated girl! extramedullary MM, myeloma cells were harvested and 
hrIL-6 for the IL&dependent HMCL, and ~irlrouf purified each day during the course of anti-IL-6 ther- 
hrIL-6 fat the autonomousty growing HMCL. Results apy. and analyzed for !L-68 gene expression, For the 
presented in Fig. 1 show that a 7.4-72.0~fold increase 3 patients, a dramatic increase of IL-6R mRNA in my- 
of IL&R mRNA level was seen after 24 h of privation eloma ce!ls was found following neutralization of ex- 
of IL-6 for XG-5 and XG-1, respectively, and that a ogenous IL-6 by the anti-6 MAb (Fig. 2). Quantification 
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Fig. 2. IL-GR gene cxprrssion in mye!omn cells from patients treated 
with anti-IL-6 MAbs. Patients A. Band C wcrc Irc:lted wilh imti-IL-G 
MAbs. Samples wcrc taken bclbrr the beginning ;md OII each day 
during the first 4 days of trc;Itmcnt, M yclomn cells wcrc enriched. total 
RNA were extrxtcd and submiltcd to hybridization with both IL-6R 
and GAPDH probes. 
24-h incubation with hrlL-6 resulted in a 83% df:crease 
of IL-6R mRNA level for RPM1 8226. 
36 
Volume 302, number 1 FEBS LETTERS May 1992 
Potlent A 
-1 0 1 2 3 4 
Day of treatment 
Patlent B 
-5 -1 1 2 2 4 
Day OP treatment 
Patient c 
-is .i i e i 
Day of treatment 
Fig. 3. Quantification of IL&R mRNA in myeloma cells in course of 
anti-IL-6 therapy. Results for each patient arc expressed in arbitrary 
units (AU), ussuming the ‘I’ value to initial content of IL-6R mRNA 
in mycloma cells beforc the beginning of trcatmcnt. 
of autoradiograms howed that this increase was at 
maximum after 3-4 days of treatment and ranged from 
6.8 (patient A) to 24.0 (patient 6) (Fig. 3). 
4. DISCUSSION 
In the present study we report the regulation of IL-6R 
gene expression by IL-6 in myeloma cells in vitro and 
in vivo. First, we showed that privation of IL-6 for 2 
IL-ddependent HMCL induced a dramatic increase of 
their amount of IL-6R mRNA. These HMCL are a 
priviliged model of study since they have retained an 
absolute requirement of exogenous IL-6 for growing in 
vitro, similarly to freshly-explanted myeloma cells 
[6,8,10]. Second, we analyzed ILdR gene expression in 
myeloma cells from 3 MM patients treated with anti-IL- 
6 MAbs. The efliciency of the anti-1 L-6 therapy to pre- 
vent binding of IL-6 to its cell surface receptor was 
shown, in these patients, by the inhibition of both the 
in vivo myeloma-cell proliferation and the production 
of C-reactive protein by hepatocytes [I I]. Indeed the 
production of this acute phase protein by human hepa- 
tocytes in primary cultures has recently been shown to 
be solely under the control of IL-6 [?I]. Results pre- 
sented here show that a significant increase of IL-6R 
mRNA occurred during the treatment of the 3 patients, 
the maximum being at 3-4 days. This relatively late 
effect can be explained by the fact that the maximal 
serum concentration of anti-IL-6 MAb was obtained 
only after 2 days of treatment in these patients (manu- 
script in preparation), Finally, a down-regulation of 
IL-6R gene expression was observed by adding hrIL-6 
to an autonomously growing HMCL, which does not 
produce IL-6 and whose growth is not affected by it [6]. 
Such a down-regulation has already been reported for 
monocytes [15,16]. 
In conclusion, the present study clearly demonstrates 
a dramatic up-regulation of IL-6R gene expression in 
IL-6-deprived myeloma cells in vitro and, interestingly, 
also in vivo. As high levels of IL-6 are produced in MM 
patients and as they reflect the disease activity, these 
results suggest hat IL-6 continuously represses the IL- 
6R gene expression in myeloma cells in vivo. Our find- 
ing of an up-regulation of IL-6R gene expression during 
anti- I L-6 therapy is of importance for the future of this 
therapy. Indeed we have recently demonstrated that 
high levels of IL-6 in the form of immune complexes 
accumulated in the plasma of patients treated with anti- 
IL-6 MAbs (manuscript in preparation!. The up-regula- 
tion of IL&R might lead to the emergence of IL-6 hy- 
persensitive tumoral subclones which are able to dis- 
place these immune complexes. thus leading to a pro- 
gressive resistance to treatment. Such a hypothesis may 
explain why a significant index of myeloma cell prolifer- 
ation was still found after one patient had been treated 
for 2 months, whereas the tumoral cell proliferation was 
still dependent on exogenous IL-B, and whereas the IL-6 
MAb was still present at this period and able to neutral- 
ize the biological activity of IL-6 on hepatocytes in vivo 
[I 11. 
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